Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAM1363 in Advanced Cancers With HER2 Alterations
NCT06253871Phase 1Recruiting
- Sponsor
- Iambic Therapeutics
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of IAM1363 in malignancy, sponsored by Iambic Therapeutics. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and 6 more. Started Mar 2024; status: recruiting.
02
Drugs
IAM1363
03
Conditions
malignancy
Beyond the preview
Go deeper on NCT06253871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253871.